ImPasstion130 Trial in TNBC

obr has 860 videos Subscribe Here

Description: Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the results of the ImPassion130, a phase III study that adds atezolizumab to 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple negative breast cancer (TNBC).
Shared By : obr
Posted on : 07/01/19
Added : 2 months ago
Category : Breast Cancer